Compared with placebo, the combination of MRA, SGLT2i, and GLP-1 RA reduced by 58% (ARR 6.9%; NNT 14) the risk of combined endpoint of HF hospitalization or cardiovascular death, 73% (ARR 6.2%; NNT 16) the risk for HF hospitalization, and 43% (ARR 3.0%; NNT 34) the risk for cardiovascular death. This evidence concerns the gene GLP1R and hydrops fetalis.